The estimated Net Worth of Michael D Loberg is at least $611 Тысяча dollars as of 29 September 2022. Mr. Loberg owns over 5,821 units of IGM Biosciences stock worth over $414,481 and over the last 18 years he sold IGMS stock worth over $0. In addition, he makes $196,105 as Independent Chairman of the Board at IGM Biosciences.
Michael has made over 48 trades of the IGM Biosciences stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 5,821 units of IGMS stock worth $114,208 on 29 September 2022.
The largest trade he's ever made was buying 39,480 units of IGM Biosciences stock on 17 November 2008 worth over $118,045. On average, Michael trades about 599 units every 23 days since 2006. As of 29 September 2022 he still owns at least 35,305 units of IGM Biosciences stock.
You can see the complete history of Mr. Loberg stock trades at the bottom of the page.
Michael D. Loberg Ph.D. serves as Independent Chairman of the Board of the Company. From January 2007 to January 2020, Dr. Loberg served on the board of directors of ArQule, a biopharmaceutical company, and was also a member of its compensation, nominating and governance committee and science committee. Dr. Loberg previously served on the board of directors of Inotek Pharmaceuticals, a biopharmaceutical company, from March 2006 to July 2014 and as Interim Chief Executive Officer from 2007 to 2009. Previously, he served as Chief Executive Officer and a member of the Board of Directors of NitroMed, a pharmaceutical company, from September 1997 to March 2006 and as its President from September 2003 to March 2006. From 1979 to 1997, Dr. Loberg held a number of senior management positions at Bristol-Myers Squibb, including President of Bristol-Myers Squibb’s Oncology and Immunology, U.S. Primary Care, Northern Europe, Specialty Pharmaceuticals and Squibb Diagnostics divisions, as well as Director and Vice President, E.R. Squibb & Sons Research and Development. Dr. Loberg received a B.S. in Chemistry from Trinity College and a Ph.D. in Chemistry from Washington University in St. Louis.
As the Independent Chairman of the Board of IGM Biosciences, the total compensation of Michael Loberg at IGM Biosciences is $196,105. There are 8 executives at IGM Biosciences getting paid more, with Fred M. Schwarzer J.D. having the highest compensation of $926,901.
Michael Loberg is 72, he's been the Independent Chairman of the Board of IGM Biosciences since 2018. There are no older and 20 younger executives at IGM Biosciences.
Michael's mailing address filed with the SEC is C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA, 94043.
Over the last 5 years, insiders at IGM Biosciences have traded over $2,263,330 worth of IGM Biosciences stock and bought 10,358,723 units worth $195,788,133 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... и Bros. Advisors Lp667, L.P.B.... On average, IGM Biosciences executives and independent directors trade stock every 13 days with the average trade being worth of $942,182. The most recent stock trade was executed by Julie Hambleton on 25 July 2024, trading 15,132 units of IGMS stock currently worth $21,033.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGM Biosciences executives and other stock owners filed with the SEC include: